NDA (New Drug Application)
Last reviewedA New Drug Application (NDA) is the application a sponsor submits to the US FDA for approval to market a new drug in the United States. It presents the evidence that the drug is safe and effective for its proposed use and that it can be manufactured to a consistent quality.
Key facts
| Regulation | 21 CFR Part 314 |
|---|---|
| Format | CTD structure, submitted as an eCTD |
| For biologics | Biologics License Application (BLA) |
| Broadly comparable in the EU | Marketing Authorisation Application (MAA) |
IND and NDA
An IND comes first and allows clinical trials to begin. The NDA comes after the pivotal trials and brings together the quality, nonclinical and clinical evidence gathered during development.

